From:  Role of immune checkpoint inhibitors in breast cancer and hematological malignancies

 FDA-approved ICIs and their indications.

Checkpoint targetICI drugApproval yearNotable trialKey biomarkersApproved indications
PD-1Pembrolizumab2014KEYNOTE-158PD-L1, MSI-H/dMMRMelanoma, NSCLC, TNBC, Hodgkin lymphoma, gastric cancer
Nivolumab2014CheckMate 227, CheckMate 142PD-L1, MSI-H/dMMR, TMBNSCLC, renal cell carcinoma, bladder cancer, colorectal cancer
PD-L1Atezolizumab2016IMpassion130, IMpassion150, IMpassion133PD-L1TNBC, urothelial carcinoma, NSCLC
Durvalumab2018PACIFIC, ADRIATIC, NCT03732677PD-L1, TILsSmall cell lung cancer, NSCLC
CTLA-4Ipilimumab2011NCT04008030, NCT01445379, NCT03408587CTLA-4, TILs, CTCsMelanoma, NSCLC (in combination with nivolumab)
LAG-3Relatlimab2022RELATIVITY-047, NICHE-3dMMR, MLH1, MSH2,
PD-L1
Advanced melanoma (in combination with nivolumab)
TIGITTiragolumab2021NCT04958811, SKYSCRAPER-11PD-L1, TAMs, Tregs, CD8+ effector T cells, serum myeloid protein markersInvestigational in NSCLC, TNBC

ICIs: immune checkpoint inhibitors; PD-1: programmed death-1; PD-L1: programmed cell death ligand 1; MSI-H/dMMR: microsatellite instability high/deficient mismatch repair; NSCLC: non-small cell lung cancer; TNBC: triple-negative breast cancer; TMB: tumor mutational burdens; TILs: tumor-infiltrating lymphocytes; CTLA-4: cytotoxic T lymphocyte-associated protein 4; CTCs: circulating tumor cells; LAG-3: lymphocyte activation gene-3; MLH1: mutL homolog 1; MSH2: mutS homolog 2; TIGIT: T cell immunoreceptor with Ig and ITIM domains; TAMs: tumor-associated macrophages; Tregs: regulatory T cells.